JP2014511682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511682A5 JP2014511682A5 JP2014501664A JP2014501664A JP2014511682A5 JP 2014511682 A5 JP2014511682 A5 JP 2014511682A5 JP 2014501664 A JP2014501664 A JP 2014501664A JP 2014501664 A JP2014501664 A JP 2014501664A JP 2014511682 A5 JP2014511682 A5 JP 2014511682A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- seq
- molecule
- sequence
- dll4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 3
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102000007562 Serum Albumin Human genes 0.000 claims 3
- 108010071390 Serum Albumin Proteins 0.000 claims 3
- 108700041286 delta Proteins 0.000 claims 3
- 101150109170 dll4 gene Proteins 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11160920 | 2011-04-01 | ||
| EP11160920.2 | 2011-04-01 | ||
| PCT/EP2012/055897 WO2012131076A1 (en) | 2011-04-01 | 2012-03-30 | BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511682A JP2014511682A (ja) | 2014-05-19 |
| JP2014511682A5 true JP2014511682A5 (enExample) | 2016-07-07 |
Family
ID=44314095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501664A Ceased JP2014511682A (ja) | 2011-04-01 | 2012-03-30 | Ｄｌｌ４及びＡｎｇ２と結合する二重特異性結合分子 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130078247A1 (enExample) |
| EP (1) | EP2694545B1 (enExample) |
| JP (1) | JP2014511682A (enExample) |
| KR (1) | KR20140016345A (enExample) |
| CN (2) | CN103596977B (enExample) |
| AP (1) | AP2013007086A0 (enExample) |
| AR (1) | AR085919A1 (enExample) |
| AU (1) | AU2012234218A1 (enExample) |
| BR (1) | BR112013025294A2 (enExample) |
| CA (1) | CA2827809A1 (enExample) |
| CL (1) | CL2013002622A1 (enExample) |
| CO (1) | CO6801638A2 (enExample) |
| EA (1) | EA201301109A1 (enExample) |
| EC (1) | ECSP13012996A (enExample) |
| MA (1) | MA35233B1 (enExample) |
| MX (1) | MX337115B (enExample) |
| PE (1) | PE20141157A1 (enExample) |
| PH (1) | PH12013502031A1 (enExample) |
| SG (1) | SG193557A1 (enExample) |
| TN (1) | TN2013000389A1 (enExample) |
| TW (2) | TWI535735B (enExample) |
| UY (1) | UY33997A (enExample) |
| WO (1) | WO2012131076A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| NZ628584A (en) * | 2012-03-30 | 2016-04-29 | Boehringer Ingelheim Int | Ang2-binding molecules |
| MX2015003894A (es) * | 2012-09-28 | 2015-07-17 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf. |
| CA2883807A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| WO2015175375A1 (en) | 2014-05-13 | 2015-11-19 | Short Jay M | Conditionally active biological proteins |
| CN107540747B (zh) * | 2017-08-09 | 2020-01-24 | 苏州大学附属儿童医院 | 抗人dll4单克隆抗体6f12 |
| CN110950967B (zh) * | 2019-12-13 | 2022-05-13 | 山东民康生物科技有限公司 | 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法 |
| CA3231417A1 (en) * | 2021-09-10 | 2023-03-16 | Jian Shi | Anti-ang2 antibody, preparation method therefor, and application thereof |
| CN116444675B (zh) * | 2023-05-11 | 2023-12-22 | 亲和(武汉)生命科技有限责任公司 | 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用 |
| WO2025111816A1 (en) * | 2023-11-28 | 2025-06-05 | Eluminex Biosciences Limited | Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2338321T3 (es) | 1992-08-21 | 2010-05-06 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| AU2001264563A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| MXPA03006358A (es) | 2001-01-17 | 2004-12-02 | Trubion Pharmaceuticals Inc | Proteinas de fusion dominio de enlace-inmunoglobulina. |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2006519763A (ja) | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| EP1558650A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| CN100343304C (zh) | 2002-12-31 | 2007-10-17 | 尼克塔治疗亚拉巴马公司 | 水解稳定的马来酰亚胺封端的聚合物 |
| EP1639011B1 (en) | 2003-06-30 | 2008-11-12 | Domantis Limited | Pegylated single domain antibodies (dAb) |
| DE60334645D1 (de) | 2003-11-07 | 2010-12-02 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| JP5489465B2 (ja) * | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法 |
| NZ572177A (en) * | 2006-06-06 | 2012-02-24 | Genentech Inc | Anti-dll4 antibodies and methods using same |
| BRPI0710411A2 (pt) | 2006-06-06 | 2012-04-10 | Genentch Inc Empresa Americana | Métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos de um antagonista de dll4 e uso de um agonisra de dll4 |
| UA94464C2 (ru) * | 2006-06-06 | 2011-05-10 | Дженентек, Инк. | Выделенное антитело к dll4 и его применение |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CN101646689A (zh) * | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CN104497143B (zh) * | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| RU2581962C2 (ru) * | 2008-09-19 | 2016-04-20 | Медиммун Ллк | Нацеленные средства связывания, направленные на dll4, и их применение |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| UY32917A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moléculas de unión a dll-4 |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
-
2012
- 2012-03-29 US US13/433,354 patent/US20130078247A1/en not_active Abandoned
- 2012-03-30 WO PCT/EP2012/055897 patent/WO2012131076A1/en not_active Ceased
- 2012-03-30 PE PE2013002157A patent/PE20141157A1/es not_active Application Discontinuation
- 2012-03-30 CN CN201280026737.XA patent/CN103596977B/zh not_active Expired - Fee Related
- 2012-03-30 KR KR1020137028119A patent/KR20140016345A/ko not_active Withdrawn
- 2012-03-30 EP EP12711200.1A patent/EP2694545B1/en not_active Not-in-force
- 2012-03-30 UY UY0001033997A patent/UY33997A/es unknown
- 2012-03-30 AU AU2012234218A patent/AU2012234218A1/en not_active Abandoned
- 2012-03-30 TW TW101111544A patent/TWI535735B/zh not_active IP Right Cessation
- 2012-03-30 EA EA201301109A patent/EA201301109A1/ru unknown
- 2012-03-30 AR ARP120101129A patent/AR085919A1/es unknown
- 2012-03-30 BR BR112013025294A patent/BR112013025294A2/pt not_active IP Right Cessation
- 2012-03-30 CN CN201610374703.XA patent/CN106046167A/zh active Pending
- 2012-03-30 TW TW101111526A patent/TWI551612B/zh active
- 2012-03-30 JP JP2014501664A patent/JP2014511682A/ja not_active Ceased
- 2012-03-30 MX MX2013011032A patent/MX337115B/es active IP Right Grant
- 2012-03-30 AP AP2013007086A patent/AP2013007086A0/xx unknown
- 2012-03-30 SG SG2013070792A patent/SG193557A1/en unknown
- 2012-03-30 CA CA2827809A patent/CA2827809A1/en not_active Abandoned
-
2013
- 2013-09-12 CL CL2013002622A patent/CL2013002622A1/es unknown
- 2013-09-26 TN TNP2013000389A patent/TN2013000389A1/fr unknown
- 2013-09-27 CO CO13230710A patent/CO6801638A2/es unknown
- 2013-09-27 MA MA36275A patent/MA35233B1/fr unknown
- 2013-09-30 PH PH12013502031A patent/PH12013502031A1/en unknown
- 2013-10-25 EC ECSP13012996 patent/ECSP13012996A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511682A5 (enExample) | ||
| JP2014515602A5 (enExample) | ||
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2015143226A5 (enExample) | ||
| JP2013502204A5 (enExample) | ||
| CL2014003637A1 (es) | Anticuerpo monoclonal optimizado que se une al gen 3 de activación de linfocitos (lag-3); molécula biespecífica que lo comprende; inmunoconjugado que comprende el anticuerpo unido a un agente terapéutico; composición; ácido nucleico; vector; célula huésped; método de preparación; y uso para inhibir el crecimiento de un tumor o tratar una infección viral. | |
| IL258215B (en) | Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody | |
| JP2010502207A5 (enExample) | ||
| JP2017524339A5 (enExample) | ||
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| JP2015532292A5 (enExample) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| WO2017009308A3 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| WO2012045882A3 (en) | Phosphospecific antibodies recognising tau | |
| JP2016502515A5 (enExample) | ||
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| BR112015012644A2 (pt) | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| WO2013059559A3 (en) | Compounds and methods for enhancing innate immune responses | |
| IL187321A (en) | Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments | |
| JP2011219478A5 (enExample) | ||
| JP2015525211A5 (enExample) |